Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the
“Company”), a biotechnology company focused on discovering and
developing novel antibody-based immunotherapies to help the immune
system fight cancer and other diseases, today announced that it will
present research findings on the Company’s novel class of anti-PD-1
antibodies in a poster at the AACR Annual Meeting 2016 in New Orleans.
Enumeral is reporting in a poster presentation at the AACR conference
that Enumeral’s anti-PD-1 antibody ENUM 244C8 appears to elicit cytokine
secretion from cell types associated with innate immunity in ex vivo
assays using lung biopsy samples from human patients. Enumeral is
advancing a novel class of anti-PD-1 antibodies with distinctive
properties compared to currently marketed anti-PD-1 antagonists,
including that ENUM 244C8 inhibits PD-1 function without blocking
binding of PD-L1 to PD-1.
Enumeral’s Abstract at AACR’s 2016 Annual Meeting
“Discovery, Characterization and Development of a New Class of
Therapeutic Anti-PD-1 Antibody.” Abstract #2224; Poster Session:
Adoptive Cell Therapy, Immune Checkpoints, and Vaccines; Monday, April
18, 2016 1:00 PM - 5:00 PM, Convention Center, Halls G-J, Poster Section
21.
About Enumeral
Enumeral is a biopharmaceutical company discovering and developing novel
antibody-based immunotherapies to help the immune system fight cancer
and other diseases. The Company is building a pipeline focused on
next-generation checkpoint modulators, with initial targets including
PD-1, TIM-3, LAG-3, TIGIT, and VISTA. In developing these molecules,
Enumeral’s researchers apply a proprietary immune profiling technology
platform that measures functioning of the human immune system at the
level of individual cells. This provides key insights for drug candidate
selection and target validation. For more information on Enumeral,
please visit www.enumeral.com.
Forward Looking Statements Disclosure
This press release contains certain “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995, as
amended. Such statements reflect current beliefs of Enumeral Biomedical
Holdings, Inc. (“Enumeral”) with respect to future events and involve
known and unknown risks, uncertainties, and other factors affecting
operations, market growth, Enumeral’s stock price, services, products
and licenses. No assurances can be given regarding the achievement of
future results, and although Enumeral believes that the expectations
reflected in these forward-looking statements are based on reasonable
assumptions, actual results may differ from the assumptions underlying
the statements that have been made regarding anticipated events. Factors
that may cause actual results, performance or achievements, or industry
results to differ materially from those contemplated by such
forward-looking statements include, among others, the risks that (a)
Enumeral’s expectations regarding market acceptance of the Company’s
business in general and the Company’s ability to penetrate the antibody
discovery and development fields in particular, as well as the timing of
such acceptance, (b) Enumeral’s ability to attract and retain management
with experience in biotechnology and antibody discovery and similar
emerging technologies, (c) the scope, validity and enforceability of
Enumeral’s and third party intellectual property rights, (d) Enumeral’s
ability to raise capital when needed and on acceptable terms and
conditions, (e) Enumeral’s ability to comply with governmental
regulation, (f) the intensity of competition, (g) changes in the
political and regulatory environment and in business and fiscal
conditions in the United States and overseas and (h) general economic
conditions.
More detailed information about Enumeral and risk factors that may
affect the realization of forward-looking statements, including
forward-looking statements in this press release, is set forth in
Enumeral’s filings with the Securities and Exchange Commission. Enumeral
urges investors and security holders to read those documents free of
charge at the Commission’s website at http://www.sec.gov.
Forward-looking statements speak only as to the date they are made, and
except for any obligation under the U.S. federal securities laws,
Enumeral undertakes no obligation to publicly update any forward-looking
statement as a result of new information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160418005244/en/
Copyright Business Wire 2016